Physician profile
James V Donovan
NPI 1629120670
$1,113.84
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,097 · 2020: $17.14.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $292.58 | 2019 | |
| Alkermes, INC. | $206.23 | 2019 | |
| Avanir Pharmaceuticals, INC. | $177.73 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $84.91 | 2019 | |
| Sunovion Pharmaceuticals INC. | $78.36 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $63.11 | 2019 | |
| Lundbeck LLC | $56.47 | 2019 | |
| Janssen Pharmaceuticals, INC | $47.88 | 2019 | |
| Vanda Pharmaceuticals INC. | $40.35 | 2019 | |
| Neurocrine Biosciences, INC. | $35.37 | 2019-2020 | |
| Neuronetics, INC. | $19.75 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $11.10 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Donovan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.